Yafeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yafeng Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Pengju Wang
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
3 shared publications - Bin Du
Zhengzhou University
1 shared publication Dandan Wang
Sino‐British Research Centre for Molecular Oncology National Centre for International Research in Cell and Gene Therapy State Key Laboratory of Esophageal Cancer Prevention & Treatment School of Basic Medical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China
1 shared publication- Fan Zhang
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & the Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, China
1 shared publication Huihui Sun
Sino‐British Research Centre for Molecular Oncology National Centre for International Research in Cell and Gene Therapy State Key Laboratory of Esophageal Cancer Prevention & Treatment School of Basic Medical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China
1 shared publication- Jinjin Shi
School of Pharmaceutical Sciences Zhengzhou University Zhengzhou China
1 shared publication
Latest Publications
- 9 December 2025
- Published by Springer Nature in Education and Information Technologies
- Vol. 31 (4) , 1203-1231
Effects of generative chatbot use in flipped classrooms on students’ higher-order thinking skills: a causal-comparative study
- 9 December 2025
- Published by Springer Nature in Education and Information Technologies
- Vol. 31 (4) , 1203-1231
Effects of generative chatbot use in flipped classrooms on students’ higher-order thinking skills: a causal-comparative study
- Open Access
- 24 June 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 102022
Engineering plasmonic Au nanostars: Enhanced plasmonic properties, preparation and biomedical application
- 24 June 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 102022
Open AccessEngineering plasmonic Au nanostars: Enhanced plasmonic properties, preparation and biomedical application
- Open Access
- 8 December 2023
- Published by Wiley in Advanced Science
- Vol. 11 (7) , e2306203
Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy
Endogenous essential metal ions play an important role in many life processes, especially in tumor development and immune response. The approval of various metallodrugs for tumor therapy brings more attention to the antitumor effect of metal ions. With the deepening understanding of the regulation mechanisms of metal ion homeostasis in vivo, breaking intracellular metal ion homeostasis becomes a new means to inhibit the proliferation of tumor cells and activate antitumor immune response. Diverse nanomedicines with the loading of small molecular ion regulators or metal ions have been developed to disrupt metal ion homeostasis in tumor cells, with higher safety and efficiency than free small molecular ion regulators or metal compounds. This comprehensive review focuses on the latest progress of various intracellular metal ion homeostasis regulation‐based nanomedicines in tumor therapy including calcium ion (Ca2+), ferrous ion (Fe2+), cuprous ion (Cu+), managanese ion (Mn2+), and zinc ion (Zn2+). The physiological functions and homeostasis regulation processes of ions are summarized to guide the design of metal ion regulation‐based nanomedicines. Then the antitumor mechanisms of various ions‐based nanomedicines and some efficient synergistic therapies are highlighted. Finally, the challenges and future developments of ion regulation‐based antitumor therapy are also discussed, hoping to provide a reference for finding more effective metal ions and synergistic therapies.
- 8 December 2023
- Published by Wiley in Advanced Science
- Vol. 11 (7) , e2306203
Open AccessNanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy
Endogenous essential metal ions play an important role in many life processes, especially in tumor development and immune response. The approval of various metallodrugs for tumor therapy brings more attention to the antitumor effect of metal ions. With the deepening understanding of the regulation mechanisms of metal ion homeostasis in vivo, breaking intracellular metal ion homeostasis becomes a new means to inhibit the proliferation of tumor cells and activate antitumor immune response. Diverse nanomedicines with the loading of small molecular ion regulators or metal ions have been developed to disrupt metal ion homeostasis in tumor cells, with higher safety and efficiency than free small molecular ion regulators or metal compounds. This comprehensive review focuses on the latest progress of various intracellular metal ion homeostasis regulation‐based nanomedicines in tumor therapy including calcium ion (Ca2+), ferrous ion (Fe2+), cuprous ion (Cu+), managanese ion (Mn2+), and zinc ion (Zn2+). The physiological functions and homeostasis regulation processes of ions are summarized to guide the design of metal ion regulation‐based nanomedicines. Then the antitumor mechanisms of various ions‐based nanomedicines and some efficient synergistic therapies are highlighted. Finally, the challenges and future developments of ion regulation‐based antitumor therapy are also discussed, hoping to provide a reference for finding more effective metal ions and synergistic therapies.
- Open Access
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1285801
The capability of heterogeneous γδ T cells in cancer treatment
γδ T cells, a specialized subset of T lymphocytes, have garnered significant attention within the realm of cancer immunotherapy. Operating at the nexus between adaptive and innate immunological paradigms, these cells showcase a profound tumor discernment repertoire, hinting at novel immunotherapeutic strategies. Significantly, these cells possess the capability to directly identify and eliminate tumor cells without reliance on HLA-antigen presentation. Furthermore, γδ T cells have the faculty to present tumor antigens to αβ T cells, amplifying their anti-tumoral efficacy.Within the diverse and heterogeneous subpopulations of γδ T cells, distinct immune functionalities emerge, manifesting either anti-tumor or pro-tumor roles within the tumor microenvironment. Grasping and strategically harnessing these heterogeneous γδ T cell cohorts is pivotal to their integration in tumor-specific immunotherapeutic modalities. The aim of this review is to describe the heterogeneity of the γδ T cell lineage and the functional plasticity it generates in the treatment of malignant tumors. This review endeavors to elucidate the intricate heterogeneity inherent to the γδ T cell lineage, the consequential functional dynamics in combating malignancies, the latest advancements from clinical trials, and the evolving landscape of γδ T cell-based oncological interventions, while addressing the challenges impeding the field.
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1285801
Open AccessThe capability of heterogeneous γδ T cells in cancer treatment
γδ T cells, a specialized subset of T lymphocytes, have garnered significant attention within the realm of cancer immunotherapy. Operating at the nexus between adaptive and innate immunological paradigms, these cells showcase a profound tumor discernment repertoire, hinting at novel immunotherapeutic strategies. Significantly, these cells possess the capability to directly identify and eliminate tumor cells without reliance on HLA-antigen presentation. Furthermore, γδ T cells have the faculty to present tumor antigens to αβ T cells, amplifying their anti-tumoral efficacy.Within the diverse and heterogeneous subpopulations of γδ T cells, distinct immune functionalities emerge, manifesting either anti-tumor or pro-tumor roles within the tumor microenvironment. Grasping and strategically harnessing these heterogeneous γδ T cell cohorts is pivotal to their integration in tumor-specific immunotherapeutic modalities. The aim of this review is to describe the heterogeneity of the γδ T cell lineage and the functional plasticity it generates in the treatment of malignant tumors. This review endeavors to elucidate the intricate heterogeneity inherent to the γδ T cell lineage, the consequential functional dynamics in combating malignancies, the latest advancements from clinical trials, and the evolving landscape of γδ T cell-based oncological interventions, while addressing the challenges impeding the field.